Abbvie Surges 1.42% on $195M Expansion as $0.72B Trading Volume Ranks 165th

Abbvie (ABBV) rose 1.42% on August 13, 2025, with a trading volume of $0.72 billion, ranking 165th in market activity. The stock's performance coincided with an announcement of a $195 million expansion of its North Chicago manufacturing facility to boost active pharmaceutical ingredient (API) production capacity in the U.S.

The investment, part of Abbvie’s broader $10 billion commitment to U.S. manufacturing over the next decade, aims to enhance domestic production of neuroscience, immunology, and oncology drugs. The new facility, set to begin construction in fall 2025 and become operational by 2027, will expand the company’s chemical synthesis capabilities. The project is expected to create at least 50 new full-time jobs within three years and strengthen Abbvie’s existing U.S. manufacturing network, which currently supports over 6,000 jobs across 11 sites.

Company leadership emphasized the strategic importance of maintaining U.S. leadership in pharmaceutical innovation. CEO Robert A. Michael highlighted the initiative’s role in advancing next-generation therapies and supporting future medical breakthroughs. Governor JB Pritzker praised the investment as a testament to Illinois’ biomanufacturing ecosystem, citing its world-class workforce and infrastructure.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to the end of the simulation achieved a 20.15% gain, demonstrating a solid return relative to passive investing benchmarks during the period.